Best Practice & Research Clinical Haematology
Volume 21, Issue 4 , Pages 691-697, December 2008

What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation?

  • Claudio Anasetti, MD (Chair, Department of Blood and Marrow Transplantation, Moffitt Cancer Center)

      Affiliations

    • Corresponding Author InformationMoffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA. Tel.: +813 745 2557; Fax: +813 745 8468.

University of South Florida, Moffitt Cancer Center, Tampa, Florida, USA

Several recipient and donor risk factors affect outcome after transplantation with allogeneic hematopoietic stem cells. The most important recipient risk factors are patient age, comorbidity, performance status, cytomegalovirus (CMV) status, and disease considerations, such as diagnosis, stage, and cytogenetic risk. Prior chemotherapy regimens, patient race, and IL10 promoter polymorphism also appear to have some impact, but to a lesser extent. The most important donor factor is the level of HLA mismatch. Donor gender, relation, age, and KIR genotype also affect outcome. Donor CMV serology, parity, and race do not appear to affect outcome. These factors must all be considered in relation to one another when selecting whether to recommend patients for transplant.

Key words: transplant, acute leukemia, patient, recipient, donor, risk factors, HLA mismatch, comorbidity, related, unrelated

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6926(08)00090-X

doi:10.1016/j.beha.2008.10.002

Best Practice & Research Clinical Haematology
Volume 21, Issue 4 , Pages 691-697, December 2008